Remove 2018 Remove Community Remove Medical Remove Relationship
article thumbnail

Episode 262: Anti-Racism in Medicine Series – Episode 18 – Remedying Health Inequities Driven by the Carceral System

The Clinical Problem Solvers

The ways to remedy the negative impacts of incarceration are to incarcerate fewer people and to invest in communities. Providing communities with the resources they need to survive, such as educational opportunities, jobs, and quality healthcare, will eliminate the need for incarceration. Hastings Cent Rep. 2022 03; 52 Suppl 1:S21-S23.

article thumbnail

Episode 120: Antiracism in Medicine Series Episode 1 – Racism, Police Violence, and Health

The Clinical Problem Solvers

Trainees may use this foundation to question how this might impact their medical education and think about this educational legacy may be reformed through curricular and structural changes at their institutions. This pathologic process can lead to adverse health outcomes affecting the cardiovascular, neurological, and endocrine systems.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Telemedicine and the Prescribing of Controlled Substances After the End of The Covid-19 Pandemic Emergency: DEA Announces Two Significant Proposed Rules: Read the Summary Below, But Learn All the Details and More at HPM’s Webinar on March 23, 2023 (Details Forthcoming….)

FDA Law

The Ryan Haight Act was enacted to address the legal “grey area” in which prescribers and pharmacies operated via the creation of two new statutory requirements: 1) the at least one “in-person” medical evaluation requirement for prescribing practitioners, 21 U.S.C. § 829(e); and 2) the modified registration requirement for online pharmacies.

article thumbnail

District Court Interprets EKRA

FDA Law

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. S&G Labs has no contractual relationships with the entities that referred clients to S&G Labs.

article thumbnail

Rethinking Opioid Conversions: Mary Lynn McPherson and Drew Rosielle

GeriPal

So, every single [inaudible 00:05:10] there is per the table, in an equianalgesic relationship to one another. So, Dr. McPherson, as far as I can tell, she’s really the only person in our professional community who in any sort of serious public way said, folks we need to do something about this. That’s one aspect of it.

IT 139
article thumbnail

Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust?

FDA Law

Janet Woodcock’s leadership, identified the need for more systematic patient engagement — a way to improve representativeness and be more proactive rather than reactive to interacting with patient communities. So, we crafted the Patient-Focused Drug Development, or PFDD, a commitment that was agreed to in PDUFA V. 28, 2020).

article thumbnail

District Court Interprets EKRA

FDA Law

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. S&G Labs has no contractual relationships with the entities that referred clients to S&G Labs.